10 Result(s)

Article

Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study

Chemotherapy for metastatic pancreatic adenocarcinoma (PDAC) primarily relies on FOLFIRINOX (LV5FU- irinotecan – Oxaliplatine) and Gemcitabine – Nab-Paclitaxel in the first-line setting. However, second-lines ...

A. Gueiderikh, A. Tarabay, M. Abdelouahab, C. Smolenschi, M. L. Tanguy… in BMC Cancer (2024)

Article

A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs

The purpose of this study was to assess the overall burden of pancreatic cancer in Europe, with a focus on survival time in a real-world setting, and the overall healthy life lost to the disease.

A. Carrato, A. Falcone, M. Ducreux, J. W. Valle… in Journal of Gastrointestinal Cancer (2015)

Article

Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II–III colorectal cancer

The aim of our study was to evaluate the prognostic role of immunological microenvironnement in stage II–III CRC patients.

N Chaput, M Svrcek, A Aupérin, C Locher, F Drusch, D Malka… in British Journal of Cancer (2013)

Article

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

A phase-III trial showed the non-inferiority of oral capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) in terms of efficacy in first-line treatment of metastatic color...

T Conroy, M Hebbar, J Bennouna, M Ducreux, M Ychou, G Llédo… in British Journal of Cancer (2010)

Article

Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer

This dose escalation study was designed to determine the maximum tolerated dose (MTD) and recommended doses (RDs) of 5-fluorouracil (5FU), folinic acid and oxaliplatin (FOLFOX) with concomitant radiotherapy in...

T Conroy, F Viret, E François, J F Seitz, V Boige, M Ducreux… in British Journal of Cancer (2008)

Article

Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial

Evaluation of new drug combinations is needed to improve patients' prognosis in advanced hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the safety and efficacy of the capecitabine–ox...

V Boige, J-L Raoul, J-P Pignon, O Bouché, J-F Blanc, L Dahan… in British Journal of Cancer (2007)

Article

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

To assess the response rate and the tolerance of irinotecan as first-line therapy, 40 patients with metastatic gastric cancer received irinotecan 350 mg m⁻² every 3 weeks administered as a 30 min infusion. Among ...

C-H Köhne, R Catane, B Klein, M Ducreux, P Thuss-Patience… in British Journal of Cancer (2003)

Article

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients

A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin®) + 5-fluorouracil (5-FU) ± folinic acid (FA), to identify predictive factor...

M A Bensmaïne, M Marty, A de Gramont, S Brienza, F Lévi… in British Journal of Cancer (2001)

Article

Cancer of the rectum

Y Bécouarn, M P Blanc-Vincent, M Ducreux, P Lasser, J B Dubois… in British Journal of Cancer (2001)

Article

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

The purpose of this study was to evaluate by a retrospective analysis of 53 patients the efficacy of chemotherapy combining etoposide and cisplatin in the treatment of neuroendocrine tumours. The regimen was a...

E Mitry, E Baudin, M Ducreux, J-C Sabourin, P Rufié… in British Journal of Cancer (1999)